top of page

Psilocybin Treatment for Depression - Clinical Insights

Psilocybin for depression is one of the most promising applications of psychedelic therapy. In particular, psilocybin therapy is being studied as an alternative to antidepressants in the treatment of treatment-resistant depression.

In this Drug Science webinar, Dr Mourad Wahba explains the science behind psilocybin for depression, which is currently in clinical trials at a number of psychedelic research centres around the world.

Dr Wahba provides an overview of psilocybin, the psychedelic experience, and how it should be implemented as a therapy, including both preparation and integration sessions.

He explains the completed and currently active clinical trials investigating psilocybin for depression, treatment-resistant depression, and existential anxiety in cancer patients. We then dive deep into the mechanism of action and safety data that has been gathered so far to give a complete overview of psilocybin.

Dr Mourad Wahba is a registrar in psychiatry and a member of the Medical Psychedelics Working Group. He is currently a clinician in the psilocybin for treatment-resistant depression trial at the Newcastle site.

Drug Science is the leading independent scientific body on drugs in the UK. We rely on donations to provide clear, evidence-based information without political or commercial interference. Drug Science webinars are free, so if you’d like to support us then please consider joining the Drug Science Community.

Keep up with developments in drug science

Reading, engaging with, and sharing our publications, papers and commentary gives evidence-based science and policy the audience it needs and deserves.

bottom of page